<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03606733</url>
  </required_header>
  <id_info>
    <org_study_id>SCS</org_study_id>
    <nct_id>NCT03606733</nct_id>
  </id_info>
  <brief_title>Suprachoroidal Injection of Triamcinolone Acetonide Using Custom Made Needle to Treat Retinal Disorders</brief_title>
  <official_title>Suprachoroidal Injection of Triamcinolone Acetonide Using Custom Made Needle to Treat Macular Diseases and Non Infectious Posterior Uveitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Marashi Eye Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Marashi Eye Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Injection in the Suprachoroidal space has potential of increasing the efficacy of the drug
      upto six times with direct effect on retinal tissues sparing the crystalline lens and
      trabecular meshwork.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A custom made 30 gauge needle offering 1000 micron penetration of the sclera at the parsplana
      with the help of gentle pressure on the sclera will help to inject medication such as
      triamcinilone or VEGF blockade agents (Ziv aflibercept or Bevacizumab) in the potential
      Suprachoroidal space which offers direct effect of injected drug on the retina and choroid
      sparing both crystalline lens, trabecular meshwork and other ocular tissues, hence improving
      efficacy of the drug upto six times and reduce potential complications such as cataract and
      glaucoma.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2018</start_date>
  <completion_date type="Anticipated">September 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Injection of triamcinilone or/ and VEGF blockade agents in the Supra Choroidal Space</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients achieved visual acuity improvement</measure>
    <time_frame>12 weeks</time_frame>
    <description>To measure best corrected visual acuity using using Snellen chart or equivalent</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Amount of Central macular thickness reduction in microns</measure>
    <time_frame>12 weeks</time_frame>
    <description>Using optical coherence tomography in monthly bases to measure central retinal thickness</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of eyes with Increased intraocular pressure</measure>
    <time_frame>12 weeks</time_frame>
    <description>To measure intraocular pressure using Goldmann applanation tonometer</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Diabetic Macular Edema, Cystoid Macular Edema, Chorodial Neovascularzation, Posterior Uveitis</condition>
  <arm_group>
    <arm_group_label>A custom made Suprachoroidal needle for macular diseases</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A custom made 30 gauge needle offering 1000 micron penetration of the sclera at the parsplana</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Custom suorachoroidal needle</intervention_name>
    <description>Custom made Supra Choroidal Space needle</description>
    <arm_group_label>A custom made Suprachoroidal needle for macular diseases</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  20 years and older

          -  Patients with macular edema or degeneration from various pathologies

          -  Central macular thickness more than 250 microns

          -  Patients who are able to come for all follow-up

        Exclusion Criteria:

          -  Significant renal disease, defined as a history of chronic renal failure requiring
             dialysis or kidney transplant.

          -  Myocardial infarction, other acute cardiac event requiring hospitalization, stroke,
             transient ischemic attack, or treatment for acute congestive heart failure within 4
             months prior to randomization

          -  For women of child-bearing potential: pregnant or lactating or intending to become
             pregnant within the next 3 years.

          -  Exam evidence of severe external ocular infection, including conjunctivitis,
             chalazion, or substantial blepharitis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ameen Marashi</last_name>
    <phone>963937785557</phone>
    <email>ameenmarashi@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Marashi Eye Clinic</name>
      <address>
        <city>Aleppo</city>
        <zip>2241511</zip>
        <country>Syrian Arab Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ameen Marashi, MD</last_name>
      <phone>963212241511</phone>
      <email>ameenmarashi@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Syrian Arab Republic</country>
  </location_countries>
  <removed_countries>
    <country>Bulgaria</country>
    <country>India</country>
  </removed_countries>
  <link>
    <url>http://medcraveonline.com/AOVS/AOVS-08-00321.pdf</url>
    <description>Treating macular edema secondary to retinal vein occlusion with suprachoroidal injection of triamcinolone acetonide using custom made needle</description>
  </link>
  <reference>
    <citation>Marashi A. Treating macular edema secondary to retinal vein occlusion with suprachoroidal injection of triamcinolone acetonide using custom made needle. Adv Ophthalmol Vis Syst. 2018;8(5):277â€’281. DOI: 10.15406/aovs.2018.08.00321</citation>
  </reference>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>July 22, 2018</study_first_submitted>
  <study_first_submitted_qc>July 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 31, 2018</study_first_posted>
  <last_update_submitted>October 25, 2018</last_update_submitted>
  <last_update_submitted_qc>October 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Marashi Eye Clinic</investigator_affiliation>
    <investigator_full_name>Ameen Marashi</investigator_full_name>
    <investigator_title>Principle investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Uveitis</mesh_term>
    <mesh_term>Uveitis, Posterior</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

